Angiex cleared to begin phase I study of TM4SF1-directed ADC

Nov. 3, 2023

Angiex Inc. has received FDA clearance of its IND application for AGX-101, a novel TM4SF1-directed antibody-drug conjugate (ADC) being developed for the treatment of solid cancers.

BioWorld Science Regulatory Cancer Antibody-drug conjugate Immuno-oncology FDA IND

Today's news in brief

BioWorld

BioWorld briefs for May 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 9, 2025.

US flag, stock market chart, White House

100 days of uncertainty

BioWorld

The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...

AI generated, 3D rendering of protein degradation

AACR 2025: Induced proximity strategy, beyond degraders

BioWorld

Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...

NME Digest: Q1 2025

BioWorld

A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...